To arrive at a recommendation, our committee examined the following questions:1. Why is living donation necessary, and is it different for patients with hepatocellular carcinoma (HCC)? 2. What is double equipoise, and how is it affected by the diagnosis of HCC? 3. Is a paired exchange appropriate if one or both recipients have HCC?
MATERIALS AND METHODSLiterature searches were conducted, and additional references were provided by committee members. Conference calls and e-mail exchanges were used to debate the relevant issues because there is a paucity of relevant published data.
ANALYSIS Question 1. Why Is Living Donation Necessary, and Is It Different for Patients With HCC?It is well established that even in countries with adequate access to deceased donor liver transplantation (DDLT), living liver donation is felt to be appropriate because of organ shortages, increasingly long waiting lists, and the expectation that many patients listed for liver transplantation will die while they are waiting for a suitable organ. The Milan criteria (a single tumor <5 cm in diameter or 2-3 lesions with individual diameters 3 cm) describe the extent of tumors in a population of patients with HCC and cirrhosis who have low recurrence rates and excellent survival rates after liver transplantation. 1 Intent-totreat studies have demonstrated that the risk of removal due to HCC progression beyond the Milan criteria (eg, the dropout rate) is greater than the risk of death while patients are awaiting transplantation.
2For these reasons, in the United States, the Organ Procurement and Transplantation Network has developed an organ allocation policy for DDLT that allows for increased priority for liver transplant candidates with stage II HCC. This policy does not apply to living donor liver transplantation (LDLT) because other candidates without HCC are not being disadvantaged.Ensuring the safety of the living organ donor and optimizing his or her care were the foci of an international forum held in 2005 in Vancouver, British Columbia. The Vancouver forum established a set of Abbreviations: DDLT, deceased donor liver transplantation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; UCSF, University of California San Francisco.